

Dear Author,

Please use this PDF proof to check the layout of your article. If you would like any changes to be made to the layout, you can leave instructions in the online proofing interface.

Making your changes directly in the online proofing interface is the quickest, easiest way to correct and submit your proof. Please note that changes made to the article in the online proofing interface will be added to the article before publication, but are not reflected in this PDF proof.

If you would prefer to submit your corrections by annotating the PDF proof, please download and submit an annotatable PDF proof by following this link:

[https://rscweb.proofcentral.com/en/offline.html?  
token=e5ff139514a5776200dc8092414fcebdc](https://rscweb.proofcentral.com/en/offline.html?token=e5ff139514a5776200dc8092414fcebdc)


We have presented the graphical abstract image and text for your article below. This briefly summarises your work, and will be presented with your article online.

1

## Development and validation of an eco-friendly HPLC-DAD method for the determination of oleuropein and its applicability to several matrices: olive oil, olive leaf extracts and nanostructured lipid carriers

Amaia Huguet-Casquero, Tania Belén López-Méndez, Eusebio Gainza and Jose Luis Pedraz

An alternative HPLC approach for oleuropein determination in olive oil, *Olea europaea* leaf extracts and nanoparticles with minimized environmental impact.



Please check this proof carefully. Our staff will not read it in detail after you have returned it.

Please send your corrections either as a copy of the proof PDF with electronic notes attached or as a list of corrections. **Do not edit the text within the PDF or send a revised manuscript** as we will not be able to apply your corrections. Corrections at this stage should be minor and not involve extensive changes.

**Proof corrections must be returned as a single set of corrections, approved by all co-authors. No further corrections can be made after you have submitted your proof corrections as we will publish your article online as soon as possible after they are received.**

Please ensure that:

- The spelling and format of all author names and affiliations are checked carefully. You can check how we have identified the authors' first and last names in the researcher information table on the next page. **Names will be indexed and cited as shown on the proof, so these must be correct.**
- Any funding bodies have been acknowledged appropriately and included both in the paper and in the funder information table on the next page.
- All of the editor's queries are answered.
- Any necessary attachments, such as updated images or ESI files, are provided.

Translation errors can occur during conversion to typesetting systems so you need to read the whole proof. In particular please check tables, equations, numerical data, figures and graphics, and references carefully.

Please return your **final** corrections, where possible within **48 hours** of receipt following the instructions in the proof notification email. If you require more time, please notify us by email to [green@rsc.org](mailto:green@rsc.org).

## Funding information

Providing accurate funding information will enable us to help you comply with your funders' reporting mandates. Clear acknowledgement of funder support is an important consideration in funding evaluation and can increase your chances of securing funding in the future.

We work closely with Crossref to make your research discoverable through the Funding Data search tool (<http://search.crossref.org/funding>). Funding Data provides a reliable way to track the impact of the work that funders support. Accurate funder information will also help us (i) identify articles that are mandated to be deposited in **PubMed Central (PMC)** and deposit these on your behalf, and (ii) identify articles funded as part of the **CHORUS** initiative and display the Accepted Manuscript on our web site after an embargo period of 12 months.

Further information can be found on our webpage (<http://rsc.li/funding-info>).

## What we do with funding information

We have combined the information you gave us on submission with the information in your acknowledgements. This will help ensure the funding information is as complete as possible and matches funders listed in the Crossref Funder Registry.

If a funding organisation you included in your acknowledgements or on submission of your article is not currently listed in the registry it will not appear in the table on this page. We can only deposit data if funders are already listed in the Crossref Funder Registry, but we will pass all funding information on to Crossref so that additional funders can be included in future.

## Please check your funding information

The table below contains the information we will share with Crossref so that your article can be found *via* the Funding Data search tool. **Please check that the funder names and grant numbers in the table are correct and indicate if any changes are necessary to the Acknowledgements text.**

Funder name	Funder's main country of origin	Funder ID (for RSC use only)	Award/grant number
Ministerio de Economía y Competitividad	Spain	501100003329	Unassigned
Euskal Herriko Unibertsitatea	Spain	501100003451	Unassigned
Secretaría de Estado de Investigación, Desarrollo e Innovación	Spain	501100007136	DI-15-07513

Q1

## Researcher information

Please check that the researcher information in the table below is correct, including the spelling and formatting of all author names, and that the authors' first, middle and last names have been correctly identified. **Names will be indexed and cited as shown on the proof, so these must be correct.**

If any authors have ORCID or ResearcherID details that are not listed below, please provide these with your proof corrections. Please ensure that the ORCID and ResearcherID details listed below have been assigned to the correct author. Authors should have their own unique ORCID iD and should not use another researcher's, as errors will delay publication.

Please also update your account on our online [manuscript submission system](#) to add your ORCID details, which will then be automatically included in all future submissions. See [here](#) for step-by-step instructions and more information on author identifiers.

First (given) and middle name(s)	Last (family) name(s)	ResearcherID	ORCID iD
Amaia	Huguet-Casquero		0000-0001-9724-0921
Tania Belén	López-Méndez		0000-0001-5029-6549
Eusebio	Gainza		0000-0002-7449-5232
Jose Luis	Pedraz		0000-0002-3938-2267

## Queries for the attention of the authors

Journal: **Green Chemistry** Paper: **d0gc00965b**

Title: **Development and validation of an eco-friendly HPLC-DAD method for the determination of oleuropein and its applicability to several matrices: olive oil, olive leaf extracts and nanostructured lipid carriers**

For your information: You can cite this article before you receive notification of the page numbers by using the following format: (authors), Green Chem., (year), DOI: 10.1039/d0gc00965b.

Editor's queries are marked like this **Q1**, **Q2**, and for your convenience line numbers are indicated like this **5, 10, 15, ...**

Please ensure that all queries are answered when returning your proof corrections so that publication of your article is not delayed.

Query Reference	Query	Remarks
Q1	Funder details have been incorporated in the funder table using information provided in the article text. Please check that the funder information in the table is correct.	
Q2	Please confirm that the spelling and format of all author names is correct. Names will be indexed and cited as shown on the proof, so these must be correct. No late corrections can be made.	
Q3	Do you wish to indicate the corresponding author(s)? If so, please specify the corresponding author(s).	
Q4	Do you wish to add an e-mail address for the corresponding author? If so, please provide the relevant information.	
Q5	Ref. 3: Please check that the last names for the 1st, 3rd, and 4th authors are displayed correctly.	
Q6	Ref. 23: Please check that the last name for the 5th author is displayed correctly.	
Q7	Ref. 29: Please check that the last name for the 1st author is displayed correctly.	

# Development and validation of an eco-friendly HPLC-DAD method for the determination of oleuropein and its applicability to several matrices: olive oil, olive leaf extracts and nanostructured lipid carriers

Cite this: DOI: 10.1039/d0gc00965b

 Amaia Huguet-Casquero,<sup>a,b</sup> Tania Belén López-Méndez,<sup>a</sup> Eusebio Gainza<sup>b</sup> and Jose Luis Pedraz<sup>a,c</sup>

Oleuropein is a natural ingredient largely used in nutritional supplements. This study reports on the development, validation and application of a HPLC method based on UV-vis detection for determining oleuropein in olive oil, olive leaf extracts and nanoparticles. The principles of green chemistry were taken into account for both sample manufacturing and HPLC method development. A Zorbax C18 column was used on which a mobile phase containing acetonitrile–water was applied in isocratic elution mode injecting 10  $\mu\text{l}$  of sample at 1.2  $\text{ml min}^{-1}$  constant flow-rate, 30  $^{\circ}\text{C}$  temperature and 15 minutes run time. Method linearity ( $r^2 > 0.999$ ) was assessed in the range of 50 to 420  $\mu\text{g ml}^{-1}$ . Precision expressed by RSD% was always better than 2%. Accuracy was in all cases within 98–102% of the expected concentration value. The sensitivity of the method was at a level of 0.08  $\mu\text{g ml}^{-1}$  as the limit of detection and at 0.25  $\mu\text{g ml}^{-1}$  as the limit of quantification. The results show that the method is suitable for the quantification of oleuropein in a variety of samples with reduced environmental impact.

 Received 18th March 2020,  
Accepted 30th April 2020

 DOI: 10.1039/d0gc00965b  
rsc.li/greenchem

## 1. Introduction

Olives and their juice are considered the cornerstone of the Mediterranean diet, which has been historically linked with higher longevity and the reduced incidence of some chronic diseases in the Mediterranean population. These health benefits have been attributed by the scientific evidence to some of the 20 types of olive polyphenols found in olive trees.<sup>1</sup> Among these, oleuropein (OLE) (Fig. 1), the major constituent of the secoiridoid family, has gained special attention. Mainly due to its hydrophilic nature as well as other factors (*i.e.* olive harvesting time, processing method) it is normally found in high quantities in olive leaves (*Olea europaea* L.) but lower (sub-ppm) in olive oil.<sup>2–4</sup> Apart from being considered one of the main ones responsible for the organoleptic properties of food it is also used for chemical standardization of marketed olive-derived products (*i.e.* olive leaf

extracts, supplements and olive oil). Beyond this, several pharmacological benefits have been attributed to this natural polyphenol during the last few decades. Even the European Medicines Agency (EMA) and the European Food Safety Authority (EFSA) have submitted their own assessment reports about its health-promoting properties in human health.<sup>5,6</sup> In particular, oleuropein has been reported to exert antiinflammatory,<sup>7</sup> platelet anti-aggregant,<sup>8</sup> antimicrobial,<sup>9</sup> hypoglycemic,<sup>10</sup> anticancer,<sup>11,12</sup> antiviral,<sup>13</sup> hypolipidemic,<sup>14</sup> antioxidant and neuroprotective<sup>15</sup> effects among others. The literature offers a long list of other natural compounds that




Fig. 1 Oleuropein.

<sup>a</sup>NanoBioCel Group, Laboratory of Pharmaceutics, University of the Basque Country (UPV/EHU), School of Pharmacy, Paseo de la Universidad 7, Vitoria-Gasteiz 01006, Spain

<sup>b</sup>Biosasun S.A., Iturralde 10, Etxabarri-Ibiña, Zigoitia, 01006, Spain

<sup>c</sup>Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Vitoria-Gasteiz, Spain

1 have also been proved to possess important pharmacological  
activities.<sup>16</sup> All these pieces of evidence, together with the  
recently increased environmental awareness, have promoted  
a trend towards the consumption of natural-origin products  
5 and thus, the use of bioactive compounds like olive polyphenols  
has gained the attention of the pharmaceutical, food  
and chemical industries. Most of these natural molecules are  
obtained from agro-industrial waste through extraction processes  
in which not only high energy consumption but also  
10 the use of large amounts of organic solvents contributes to  
its overall environmental impact. Therefore, both from a  
toxico-pharmacological and ecofriendly point of view, those  
harmful aspects should be minimized through the application  
of green chemistry.

15 Another issue that must be addressed to achieve the  
required properties of olive polyphenol based by-products is  
their lability against both external and systemic factors.  
Specifically, OLE is rapidly degraded after light and oxygen  
exposure and once in the human organism its bioavailability  
20 is compromised by enzymatic degradation and limited absorption  
in the target site.<sup>17–19</sup>

Taking into account the aforementioned facts, polymeric  
and lipid-based nanoparticles have been proposed as innovative  
25 drug delivery systems (DDS) that could protect and  
improve the efficacy of the encapsulated compounds until  
their release in the target site. Among these DDS, nanostructured  
lipid carriers (NLC) offer several advantages such as the  
avoidance of organic solvents during the manufacturing  
30 process, higher drug loading, long-term stability and scaling-up  
feasibility.<sup>20,21</sup> In order to determine the yield of the nanoformulation  
process, the amount of encapsulated drug should be quantified  
and thus, precise analytical methods are needed.

35 High performance liquid chromatography (HPLC) coupled  
with a diode array detector (DAD) is one of the most common  
analytical methods in the pharmaceutical and food industries  
for routine quantification analysis. More specifically, reverse  
phase (RP)-HPLC has emerged as a sensitive, rapid and accurate  
40 technique that allows the separation and determination of  
analytes in several nutraceutical and pharmaceutical forms  
including nanoparticles.

45 As a result, several HPLC methods have been reported for  
oleuropein quantification in olive leaves and olive leaf  
extracts,<sup>22,23</sup> olive oil,<sup>24,25</sup> olive stems and roots,<sup>4</sup> and olive  
pomace and fruit.<sup>26</sup> However, they have some limitations such  
as the use of large amounts of organic solvents due to long  
50 analysis time, lack of validation results, more complex  
methods using gradients and mass detectors, tedious sample  
preparation techniques and lack of method applicability for  
the quantification of oleuropein in nanoparticle formulations.

55 Taking the aforementioned, the goal of the present work  
was to validate a rapid and versatile RP-HPLC-DAD method  
for the determination of oleuropein in olive oil, olive leaf  
extracts and nanoparticles obtained through eco-friendly  
processes.

## 2. Materials and methods

### 2.1. Materials

1 An oleuropein reference standard (>98% purity) was purchased  
from Sigma-Aldrich (St Louis, MO). Oleuropein (>80% purity)  
5 for nanoencapsulation was kindly donated by Nonaherbs Bio  
(Tech) (China). Olive leaf, organic extra virgin olive oil (EVOO)  
and organic extra virgin olive oil rich in olive polyphenols  
(EVOO-ph) were donated by Biosasun S.A. (Álava, Spain).  
10 HPLC-grade methanol (MeOH), acetonitrile (ACN) and ortho-  
phosphoric acid (85%) were purchased from Scharlab®. Water  
(H<sub>2</sub>O) was purified in a Milli-Q Plus system (Millipore®) with a  
conductivity of 18.2 MΩ·cm at 25 °C. Precirol® ATO 5 (Glycerol  
15 distearate) was a kind gift from Gattefosé (France).  
Polysorbate, Tween®80 was purchased from Panreac Química  
(Castellar del Vallès, Barcelona, Spain). Poloxamer 188 was  
kindly provided by Merck (Darmstadt, Germany). All other  
20 reagents and solvents used in this study were of analytical  
grade.

### 2.2. Instrumentation

25 A Waters 2795 Alliance HPLC system (Waters Corporation,  
Milford, MA, USA) equipped with a binary HPLC pump  
(Waters 2487), a diode array detector (Waters 2489), a column  
oven (Waters Column Heater Module), and an auto sampler  
(Waters 717 plus Autosampler) was used. Data acquisition,  
analysis and reporting were performed using Empower 2  
30 chromatography software (Milford, MA, USA). Analysis was  
performed using a Zorbax® C18 column (Agilent, Wilmington,  
DE, USA) with 5 µm in particle size, 4.6 mm in internal diameter  
and 250 mm in length.

### 2.3. Chromatographic conditions

35 Separation of OLE was performed in isocratic mode with a  
mobile phase consisting of a mixture of ACN–H<sub>2</sub>O (20 : 80, v/v).  
The pH of the mobile phase was adjusted to 3.0 using ortho-  
phosphoric acid. The mobile phase was degassed in an ultra-  
sonic bath for 15 minutes before analysis. The analysis was  
40 carried out at 1.2 mL min<sup>-1</sup> flow rate with a detection wave-  
length of 230 nm and the injection volume was arranged as  
10 µL. Column temperature was set to 30 °C. Method run time  
was 15 min. All tested samples were filtered through a 0.45 µm  
pore-size polyvinylidene fluoride (PVDF, Scharlau®) filter prior  
45 to analysis. Each working day injection was carried out after  
pre-conditioning of the column at the optimized temperature  
(30 °C) and flow rate for 15 min.

### 2.4. Preparation of standard solutions

50 Standards were prepared in deionized water and filtered  
through a 0.45 µm pore size PVDF-filter before injection. All  
standards were protected from light. A stock standard solution  
of 1 mg ml<sup>-1</sup> was prepared in Milli-Q water. Seven working  
55 standard solutions (50, 75, 100, 280, 350, 385 and 420 µg ml<sup>-1</sup>)  
were prepared by diluting in Milli-Q water the corresponding  
aliquots of stock standard solution in 5 ml amber volumetric  
flasks.

## 2.5. System suitability

System suitability testing is essential for the assurance of the quality performance of the chromatographic system. For this purpose, six replicates of the OLE reference standard at a concentration of 280  $\mu\text{g mL}^{-1}$  were analyzed. System performance and chromatographic parameters such as the number of theoretical plates ( $N$ ), tailing factor ( $T$ ), resolution ( $R_s$ ) and capacity factor ( $k'$ ) were taken into consideration.

## 2.6. Method validation

The analytical method for the quantification of OLE was validated according to the International Conference on Harmonization (ICH) guidelines Q2 (R1)<sup>27</sup> in terms of specificity, selectivity, linearity, range, precision, accuracy, limit of detection (LOD) and limit of quantification (LOQ).

**2.6.1. Linearity.** Linearity was determined at seven different concentration levels (50, 75, 100, 280, 350, 385 and 420  $\mu\text{g mL}^{-1}$ ). Experiments were carried out in triplicate. Peak areas were plotted against the analyte concentration to obtain a regression line. The linear calibration function was fitted by the least-squares methodology.

The range of the method was validated by checking the interval between the upper and lower concentrations (amounts) of the analyte in the sample (including these concentrations) for which it has been demonstrated that the analytical procedure has a suitable level of precision, accuracy and linearity.

**2.6.2. Specificity.** In order to demonstrate that no interference occurred due to the other sample constituents, a specificity test was carried out by comparing the chromatograms obtained from the EVOO hydroalcoholic extraction solution (MeOH–H<sub>2</sub>O, 50 : 50, v/v), deionized water, mobile phase and supernatant of blank nanoparticles (without OLE) with the OLE reference standard solution and samples containing OLE.

**2.6.3. LOD and LOQ.** In this study a calibration curve was prepared at low concentrations (0.2  $\mu\text{g mL}^{-1}$ , 0.4  $\mu\text{g mL}^{-1}$ , 0.6  $\mu\text{g mL}^{-1}$ , 1  $\mu\text{g mL}^{-1}$  and 6  $\mu\text{g mL}^{-1}$ ). This method can be applied in all cases, and it is most applicable when the analysis method does not involve background noise. It uses a range of low values close to zero for the calibration curve, and with a more homogeneous distribution will result in a more relevant assessment. The LOD and LOQ were assessed by applying the following equations:

$$\text{LOD} = \frac{3.3\sigma}{S}$$

$$\text{LOQ} = \frac{10\sigma}{S}$$

Where  $\sigma$  is the standard deviation of the response of ten blank samples and  $S$  is the slope of the calibration curve.

**2.6.4. Precision.** Precision is a measure of how close results are to one another. Precision of the method was determined by repeatability (intra-day precision) and intermediate precision (inter-day precision) studies. Intra-day precision was assessed by analyzing three replicates of the standard solu-

tions: at three levels of low (50  $\mu\text{g mL}^{-1}$ ), medium (280  $\mu\text{g mL}^{-1}$ ) and high (420  $\mu\text{g mL}^{-1}$ ) concentrations on the same day. Inter-day precision was evaluated through the analysis of three levels of the standard solutions at low (50  $\mu\text{g mL}^{-1}$ ), medium (280  $\mu\text{g mL}^{-1}$ ) and high (420  $\mu\text{g mL}^{-1}$ ) concentration levels in three different days. Results were expressed as relative standard deviation (RSD).

**2.6.5. Accuracy.** Accuracy is the closeness of the test results obtained by the analytical method to the true value. With this aim and following ICH Q2(R1)<sup>27</sup> recommendations, accuracy of the method was studied by the addition of known amounts of OLE to blank samples, working at the three concentration levels in the linear range previously established for the analyte (50, 280 and 420  $\mu\text{g mL}^{-1}$ ). From the obtained data the average recovery values of the lowest, intermediate and upper concentration levels were calculated.

## 2.7. Method applicability and sample preparation

All samples were prepared by dilution in deionized water with the exception of EVOO and EVOO-ph for which an extraction process was carried out.

**2.7.1. Organic extra virgin olive oil rich in polyphenols (EVOO-ph).** Organic *Olea europaea* fruit juice rich in olive polyphenols (EVOO-ph) was obtained from organic olives of Arroniz and Arbequina varieties following the protocols of Biosasun. Briefly, olives were harvested in early November, when the fruit is yet in a low ripening index, and leaves were discarded. Immediately after, olives were ground and centrifuged in a horizontal centrifuge (Baby 2-l, Peralisi MAIP SPA, Zaragoza, Spain) at low temperature (<27 °C). The obtained product was kept in High Density Polyethylene (HDPE) containers for decantation for 2 months at low temperature (<27 °C) and finally, packaged in amber bottles. EVOO was also obtained through the same methodology but only Arroniz variety olives were employed.

With the aim to determine the OLE content in EVOO-ph through the validated HPLC method, it was processed through a simple and rapid method. Briefly, EVOO-ph was subjected to sonication in a water-bath for 15 minutes in order to obtain a homogeneous sample. Then, 4 grams of the sample were diluted in 20 ml of a MeOH–H<sub>2</sub>O (50 : 50, v/v) solution and left to mix under magnetic stirring for 4 hours. After that, the obtained solution was filtered through a 0.45  $\mu\text{m}$  pore-size PVDF-filter prior to its analysis by the validated HPLC method. As a blank-control, pure EVOO was also processed as aforementioned and analysed.

**2.7.2. Organic *Olea europaea* L. extracts.** Organic olive leaves discarded during the olive oil manufacturing process were used for OLE extraction. Briefly, *Olea europaea* dried leaves (10 kg) were ground and introduced into a brew bag. Solid-liquid extraction was conducted by immersing the brew bag into a pre-heated water bath (50 L, 80 °C) for 4 hours. After extraction, the aqueous solution of olive polyphenols was stored at 4 °C and protected from light, until use. The *Olea europaea* L. extract was also subjected to a freeze-drying process for 42 hours (Telstar Lyobeta freeze-dryer, Terrasa,

**Table 1** Freeze-drying process steps for *Olea europaea* L. extracts

Freeze-drying step	Temperature (°C)	Time (hh mm)	Pressure (mBar)
Freezing	-50	3 h 00 min	—
Chamber vacuum			0.2
Primary Drying	-50	5 h 00 min	0.2
	20	7 h 00 min	0.2
Secondary Drying	20	24 h 00 min	—

Spain). For this purpose, the following drying cycle was programmed: freezing for 3.0 h, primary drying for 12 h, and secondary drying for 24 h. The pressure was set to 0.2 mBar during the primary drying. Table 1 summarizes the exact parameters of the process.

Enumeration of moulds and yeast in the obtained *Olea europaea* L. aqueous and freeze-dried extracts was conducted following the ISO 21527-1:2008 and ISO 21527-2:2008 guidelines.

In order to quantify the OLE content in the obtained aqueous and freeze-dried extracts, they were diluted 1:20 and 1:1 in deionized water, respectively, and filtered through a 0.45 µm pore-size PVDF-filter prior to its analysis by the validated HPLC method.

**2.7.3. Oleuropein-loaded nanostructured lipid carriers (NLC-OLE).** For OLE nanoencapsulation, a commercial OLE powder (purity > 80%, Nonaherbs®) from olive leaves was employed. OLE-loaded nanoparticles were obtained by the hot melt homogenization method as previously described by our group.<sup>28</sup> Briefly, EVOO (liquid at room temperature) and the solid lipid Precirol ATO® 5 (melting point: 56 °C) were mixed and melted 5 °C above the solid lipid melting point until a clear and homogeneous phase was obtained. The aqueous phase was prepared by dispersing Tween® 80 and Poloxamer 188 in purified water. Oleuropein was also dissolved in purified water (0.66 mg ml<sup>-1</sup>). When the lipid phase was melted and the aqueous phase was heated to the same temperature, oleuropein solution was added to the lipid phase and immediately after, the hot aqueous phase was added to the melted oily phase, and then sonicated at 50 W (Branson Sonifier 250, Danbury, CT, USA). The obtained nanoemulsion was mixed by magnetic stirring at room temperature and then stored for 2 h at 4 °C to allow the re-crystallization of the lipids and NLC formation. Afterwards, particles were collected using a 100 kDa molecular weight cut-off centrifugal filter unit (Amicon, “Ultracel-100 k”, Millipore, Spain) by centrifugation at 2500 rpm and washed three times with MilliQ water. The obtained supernatants were collected to determine by HPLC the encapsulation efficiency. Blank-NLCs without OLE were also prepared and used as the control.

OLE content in nanoparticles was assessed by an indirect method. The supernatant obtained from the ultracentrifugation process was diluted 1:10 in water, and filtered through a 0.45 µm pore-size PVDF-filter and the analyte concentration was determined by the validated HPLC method. Blank-NLCs

without OLE were analysed as the control. Encapsulation efficiency was calculated following the equation:

$$EE (\%) = \frac{\text{Total amount of OLE} - \text{Amount of free OLE}}{\text{Total amount of OLE}} \times 100$$

## 2.8. Greenness evaluation of the HPLC method for olive-derived samples

With the aim to assess the impact of the proposed method on health and environment the Environment Assessment Tool (EAT) free software developed by Gaber *et al.* was employed.<sup>29</sup> This tool is based on the type and amount of organic solvents used in sample/standard pre-treatment and mobile phase preparation, as well as the elution program employed (isocratic or gradient). Other factors involved in the energy-consumption are not taken into account (*i.e.* temperature, type of detector). Therefore, to conduct this assessment the type and amount of solvents employed for each sample preparation were introduced in the tool, as well as, the chromatographic conditions (flow rate, mobile phase composition, analysis time) and the safety (*S*), health (*H*) and environment (*E*) impacts were obtained. The sum of *S*, *H* and *E* gave the total EAT value. For this metric, the higher the score, the greener the method. Calculation is performed according to the following equation:

$$\text{HPLC} - \text{EAT} = S1m1 + H1m1 + E1m1 + S2m2 + H2m2 + E2m2 + \dots + Snmn + Hnmn + Enmn$$

where *S*, *E* and *H* are safety, environmental and health factors, respectively, for *n* number of solvents and *m* is the mass of the solvent. Mobile phases composed of either pure H<sub>2</sub>O or H<sub>2</sub>O containing buffer salts and/or analytical modifiers are considered to have zero *E*, *H* and *S*, values due to the outweighing effect of organic solvents. Detailed information is provided elsewhere.<sup>29</sup> Furthermore, we employed the EAT tool to rank the greenness of the different HPLC methods for OLE quantification found in the literature and we compared them with our method.

## 2.9. Statistical analysis

The statistical analysis of the validation data was performed using EMPOWER PRO 2 software (Milford, MA, USA). The Environment Assessment Tool (EAT) was employed for the greenness evaluation of the HPLC method.

# 3. Results and discussion

## 3.1. Method development

The proposed RP-HPLC-DAD method was developed with the aim to provide a simple and versatile technique for OLE quantification in different samples derived from organic certified olive trees and obtained by green methods, with shortened time and cost analysis.

HPLC is a powerful analytical technique and one of the most widely employed ones in industry. Among these, the most popular is RP-HPLC which usually uses mixtures of water



and ACN. Despite the toxicity of ACN, replacing it with another non-toxic solvent such as alcohols is not an easy work due to the advantages that H<sub>2</sub>O–ACN mixtures can offer in efficient RP-HPLC separation methods (*i.e.* better separation efficiencies, lower viscosity, and higher transparency in the UV region). Therefore, with the aim to reduce the volume of organic waste by shortening the retention time of OLE and reducing the amount of ACN employed in the mobile phase as well as effectively separating the OLE peak in compliance with ICH Q2(R1)<sup>27</sup> requirements, a new RP-HPLC-DAD method for OLE determination was developed, based on previous work of our group and from an eco-friendly perspective.

Previously, our group defined a gradient method for OLE determination (ultrapure water with orthophosphoric acid \*pH = 3 as eluent A and ACN as eluent B) (data not published). The gradient started at 5% of eluent B and increasing to 20% in 6 min, and remained constant until minute 10. At this time eluent B was increased to 100% and maintained for 3 minutes. At minute 13, eluent B was decreased to 5% and kept constant until minute 18. The injection volume was 20 µl, the flow rate was 1 ml min<sup>-1</sup> and the detector wavelength was set to 280 nm. Acetic acid was also assayed for pH adjustment in eluent A but since it gave a small signal in the baseline it was discarded. With this method, OLE eluted at minute 9.3 but no resolution was achieved in real samples and high noise was detected in the baseline. Since OLE eluted when the mobile phase composition was ACN–H<sub>2</sub>O (20 : 80 v/v) we decided to try it in isocratic mode, keeping the other chromatographic parameters constant. Baseline noise was eliminated and oleuropein displayed the same retention time as before. The Zorbax extended C-18 column was employed for these tests and lack of reproducibility was shown, probably due to the fact that this column is more suitable for high pH values. Therefore, due to its long-term stability and suitability at low pH values, as well as its properties we decided to try a Zorbax SB-CN C18 column and better peak shape and reproducibility were achieved. Taking the aforementioned, ACN and H<sub>2</sub>O were selected as mobile phase solvents and pH was always adjusted to 3.0 with orthophosphoric acid. Initially, several ACN–H<sub>2</sub>O proportions were assayed with the OLE reference standard, commercial OLE extract and olive leaf aqueous extract and results were studied to obtain acceptable retention times, good symmetry, shape and separation between peaks. Results are displayed in

Table 2. Despite the fact that shortened retention time was obtained with ACN–H<sub>2</sub>O (25 : 75, v/v, \*pH 3.0), retention factor (*k'*) and resolution values were lower or too close to the acceptance criteria (*R<sub>s</sub>* > 1.5) in the studied samples. Therefore, the mobile phase composed of ACN–H<sub>2</sub>O (20 : 80, v/v, \*pH 3.0) was selected for the following optimisation steps. The detector wavelength was set to 255 and 230 nm, and as 230 nm gave a significantly higher area value for the same oleuropein concentration it was selected as the best one. All the development processes were carried out with the analyte dissolved in water. However, theory states that better results are obtained when a sample is dissolved in the mobile phase and based on bibliography, oleuropein seemed to have better results when dissolved in methanol and thus, both solvents were assayed as well as water. No significant differences were obtained in the peak quality parameters (data not shown) and since one of the objectives of this method was to keep the organic solvent use to a minimum, water was selected as the sample dissolution medium. Finally, column temperature was adjusted to 30 °C in order to slightly improve the resolution and reduce the retention time from 12 to 11 minutes.

### 3.2. Method validation

Method validation was carried out following ICH Q2 (R1) guidelines.<sup>27</sup>

**3.2.1. System suitability.** Once the method was optimized with the best conditions, the system suitability parameters were investigated. Since ICH Q2 (R1) guidelines<sup>27</sup> do not indicate any acceptance criteria to evaluate the system suitability, US Food and Drug Administration (FDA) guidelines and European Pharmacopoeia (EP) established criteria for HPLC methods of pharmaceutical analysis were followed.<sup>30</sup> Therefore, the analyte capacity factor (*k'*), peak symmetry or tailing factor, number of theoretical plates (*N*) and resolution (*R<sub>s</sub>*) were investigated. As shown in Table 3, the developed method accomplished the acceptance criteria for all the studied parameters in the OLE reference standard.

**3.2.2. Specificity.** The specificity test allows to verify if the method is selective enough to quantify the analyte of interest in the presence of other substances that can interfere in the analysis of a complex sample. To assess this, the retention times of OLE standard and samples solutions' chromatograms were compared (Fig. 2). Moreover, blank samples' chromato-

**Table 2** HPLC method development results

Mobile phase composition (ACN : H <sub>2</sub> O)	Sample	Results			
		<i>k'</i> (2 > <i>k</i> < 10 <sup>b</sup> )	Resolution (>1.5) <sup>b</sup>	Symmetry (>1) <sup>b</sup>	<i>R<sub>T</sub></i> (min)
25 : 75	Oleuropein reference standard	1.53 <sup>a</sup>	—	1.14	7.4
	<i>Olea europaea</i> L. extract	1.59 <sup>a</sup>	1.54	1.14	7.5
	Oleuropein for nanoencapsulation	1.59 <sup>a</sup>	1.56	1.19	7.4
20 : 80	Oleuropein reference standard	2.74	—	1.21	11.0
	<i>Olea europaea</i> L. extract	2.83	2.62	1.16	11.1
	Oleuropein for nanoencapsulation	2.79	2.84	1.17	11.0

<sup>a</sup> Results that do not accomplish acceptance criteria. <sup>b</sup> Acceptance criteria. *r<sub>T</sub>* (retention time).


**Table 3** Results from the system suitability study

Parameter	Acceptance criteria	Results
Theoretical plates ( $N$ )	EP: $\geq 1000$ FDA: $>2000$	11 474.47 11 270.17
USP tailing ( $T$ )	FDA: $\leq 2$	$1.21 \pm 0.01$
Symmetry factor EP	EP: 0.8 to 1.5	
Capacity factor ( $k$ )	EP: $\geq 2$ FDA: $>2$	2.743
$R_T$ %RSD	EP: $\leq 2$ FDA: $\leq 2$	0.04

grams were studied. Similar retention times ( $\sim 11$  min) were observed in the chromatograms of the standard and sample solutions. Furthermore, no interfering peaks were observed in the blank chromatograms (Fig. 2B, D, and F). The chromatograms of the samples also showed other peaks of unknown compounds that absorb in the same wavelength as OLE. Nevertheless, good resolution was shown for these peaks that did not co-elute with the OLE peak, so they did not interfere in the analysis (Fig. 2A, C, E and G). Therefore, the proposed chromatographic method offered an adequate selectivity for OLE analysis in EVOO, olive leaf extracts and NLCs.

**3.2.3. Linearity.** Based on the analysis of seven concentrations from 50 to 420  $\mu\text{g ml}^{-1}$ , in triplicate, the linearity of the developed analytical method was evaluated (Fig. 3). The square of correlation coefficient ( $r^2$ ) value was found to be over the acceptance criteria ( $>0.999$ ) indicating that the developed method is linear in the considered range. Therefore, a good linearity was established over the studied range (50–420  $\mu\text{g ml}^{-1}$ ) demonstrating the suitability of the proposed method.

**3.2.4. LOD and LOQ.** The lowest concentration at which an analyte can be detected (LOD) or quantified (LOQ) with acceptable precision and accuracy was calculated from the standard deviation of the response and the slope obtained from the linear regression of a calibration curve with concentrations close to zero (Table 4). To assess these parameters, the follow-

**Fig. 3** Regression data and curve of the calibration curve for quantitative determination of OLE by HPLC.


ing eight concentrations were prepared and analysed in triplicate: 0.2  $\mu\text{g mL}^{-1}$ , 0.4  $\mu\text{g mL}^{-1}$ , 0.6  $\mu\text{g mL}^{-1}$ , 1  $\mu\text{g mL}^{-1}$ , and 6  $\mu\text{g mL}^{-1}$ . According to the obtained results, the LOD was found to be 0.08  $\mu\text{g mL}^{-1}$ , whereas the LOQ was found to be 0.25  $\mu\text{g mL}^{-1}$ .

**3.2.5. Precision.** For precision analysis, OLE standard solutions (50, 280 and 420  $\mu\text{g mL}^{-1}$ ) were prepared in triplicate, and analyzed on the same day (repeatability) or in three different days (intermediate precision). As shown in Table 5 both repeatability and intermediate precision did not exceed the maximum established RSD value:  $\leq 2$ . The highest RSD value was found to be 1.92%. Therefore, the good precision of the method was confirmed.

**3.2.6. Accuracy.** In the present work, the accuracy of the method was studied using the average recovery values of the lowest, intermediate and upper concentration levels of the cali-

**Table 4** Curve calibration parameters for LOD and LOQ determination

Linearity parameter	Reference standard solution
Linearity range ( $\mu\text{g ml}^{-1}$ )	0.2–6.0
Slope	7.98
Intercept	0.44
Determination coefficient ( $r^2$ )	0.9994
Correlation coefficient ( $r$ )	0.9997
SD of slope	0.06
SD of intercept	0.20

**Fig. 2** Chromatograms of the NLC-OLE supernatant (A), Blank-NLC supernatant (B), *Olea europaea* L. aqueous extract (C), Water (D), EVOO-ph (E), EVOO (F), OLE for nanoencapsulation (purity  $> 80\%$ , Nonaherbs®) (G), and OLE reference standard (H).

**Table 5** Results from intra-day (repeatability) and inter-day (intermediate) precision studies

Level	Intra-day		Inter-day	
	% of recovery	RSD (%)	% of recovery	RSD (%)
Low	100.3	0.53	101.0; 99.2; 101.8	1.34
Medium	98.8	1.92	101.1; 99.1; 102.5	1.72
High	102.9	0.71	100.5; 99.5; 102.9	1.72

bration curve (50, 280 and 420  $\mu\text{g ml}^{-1}$ ), covering the linear range of the analyte. The supernatant of empty nanoparticles, distilled water and EVOO extraction solution were spiked with OLE standard solutions and analysed after three repeated injections for each sample, in triplicate. Results were expressed as the percentage of recoveries with their respective RSD (Table 6). For all samples at the three concentration levels tested, recovery was within  $100 \pm 1.89\%$ . Since RSD values were  $\leq 2$ , accuracy of the method was confirmed.

### 3.3. Method applicability to real samples

The developed and validated method in this work was proposed to study the presence of OLE in different sample matrices obtained through environmentally friendly processes. More specifically, we looked for an analytical method that with reduced organic solvent use could be able to quantify the OLE content in EVOO, *Olea europaea* L. extracts and EVOO based nanoparticles. Results are summarized in Table 7. The European Food Safety Authority has released a claim concerning the effectiveness of the ingestion of olive polyphenols on protecting low-density lipoprotein cholesterol (LDL) from oxidative stress (Commission Regulation (EU) 432/2012). On this basis, marketed olive oils should have a minimum content of 5 mg of oleuropein (or related polyphenols) per 20 grams of product in order to be acknowledged with the proposed health claim ("*Olive oil polyphenols contribute to the protection of blood lipids from oxidative stress*"). However, these polyphenols are rarely found in regular olive oils and thus, it is difficult to find these products in the market labelling the claim. In fact, we have only detected three of them in the market: Oleohealth®, Oliveheart® and Secret to live®. Nevertheless, the last one corresponds to a food supplement composed of olive oil with the addition of olive leaf extract. Evidence suggests that specific factors such as the ripening state of the olive on harvest time, olive variety and olive oil processing method (temperature and pressure) have an important influence on that.<sup>31–33</sup> Other authors state that it is a consequence of the

**Table 7** OLE quantification from different samples. Results are expressed as mean  $\pm$  standard deviation

Sample	Oleuropein content
EVOO-ph ( $\text{mg g}^{-1}$ )	$0.52 \pm 0.03$
<i>Olea europaea</i> L. aqueous extract ( $\text{mg g}^{-1}$ )	$5.18 \pm 0.1$
<i>Olea europaea</i> L. freeze-dried extract ( $\text{mg g}^{-1}$ )	$115.01 \pm 1.94$
NLC-OLE supernatant ( $\text{mg ml}^{-1}$ )	$30.62 \pm 0.06$

lack of adequate analytical methods to quantify OLE and related hydroxytyrosol and tyrosol in olive oils.<sup>34</sup> Routine analysis techniques for olive oils employ two-step extraction methods. Firstly, an extraction process with n-hexane is normally conducted to discard fat components followed by one or two hydroalcoholic extraction steps. In this work, the first step was avoided and extraction with MeOH–H<sub>2</sub>O (50:50, v/v) seemed to be enough for OLE isolation. Other authors have proved that the defatting step led to a difference of 3% in the obtained results and thus, from an environmental point of view, in our case, it was not an essential step to carry out. Following our validated method, EVOO-ph showed a concentration of 0.52 mg per gram of oil (Table 6) whereas EVOO did not exert any signal. Taking into account these results, the intake of at least 10 gr of EVOO-ph might be enough for protecting LDL from oxidation and thus, the product accomplishes the requirements for labelling the aforementioned claim. Beyond this health claim, the truth is that currently there is no recommended dose for oleuropein or toxicity established for this compound and related phenols. Evidence in clinical trials suggests that oleuropein is safe in high doses up to 240 mg per person per day. Susalit *et al.* reported in a clinical study with hypertensive patients that the intake of 200 mg per person per day of oleuropein could effectively lower blood pressure in subjects with stage-1 hypertension and that the only side effects that might be related to this polyphenol may include headache and muscle discomfort.<sup>35</sup> In other clinical trials it was demonstrated that a daily intake of 51.1 mg of oleuropein combined with 9.7 mg of hydroxytyrosol for 12 weeks significantly improved insulin sensitivity and pancreatic  $\beta$ -cell secretory capacity in men at risk of developing metabolic syndrome.<sup>36</sup> In contrast, Castañer *et al.* also demonstrated the effectiveness of the intake of only 25 ml per day of high polyphenol content olive oil (around 8 mg of total polyphenols/person per day) to reduce systemic cardiovascular risk factors and the possibility to modulate genes involved in some chronic degenerative diseases.<sup>37</sup> Therefore, clinical data suggest that most of the pharmacological effects of these poly-

**Table 6** Results from the accuracy study

OLE ( $\mu\text{g ml}^{-1}$ )	Distilled water Recovery (%)	NLC-Supernatant RSD (%)	EVOO extraction solution			
			Recovery (%)	RSD (%)	Recovery (%)	RSD (%)
50	100.3	0.53	99.0	1.43	102.5	1.08
280	98.8	1.89	97.3	1.62	99.0	0.79
420	102.9	0.73	98.0	0.95	97.8	1.80

phenols need the intake of such an amount that could not be reached with the maximum recommended intake of olive oil per person per day. As a result, *Olea europaea* L. extracts emerge as an alternative source of olive polyphenols. In this work, *Olea europaea* L. aqueous extract was obtained through a green extraction method, using high temperatures and distilled water. The use of any organic solvent was avoided during the extraction process. Unknown peaks (probably other minor polyphenols) were found in the chromatograms of the studied extracts but the OLE peak showed good resolution ( $>1.5$ ) and thus, no peak interfered in OLE quantification, indicating that the method was valid for OLE analysis in these samples. Aqueous extracts offer several advantages such as better bioactivity and less toxicity than their organic equivalents. However, they are most likely to be contaminated with yeast and molds because of their high water content and, at the same time, low concentration of the bioactive compounds is normally found in these kinds of extracts, especially when obtained through solvent-free extraction processes.<sup>38</sup> In industrial processes extraction is normally followed by a purification step, in which the main disadvantage is not only the high energy consumption but also the excessive use of organic solvents. Whilst several efforts have been made to minimize the use of hazardous solvents during extraction, this is not possible for the purification steps which are usually based on industrial-scale chromatography methods. Aimed to address this issue, we proposed the application of freeze-drying as a greener alternative for the purification of OLE which offers less harmful residues and lower waste amounts than conventional large-scale chromatography. Freeze-drying is a common process in the pharmaceutical, biotechnological and nutraceutical industries normally employed for improving the shelf life and storage capabilities of drugs and natural compounds. From a biological point of view, freeze-drying is also used for yeast preservation with the addition of cryoprotectants. However, some authors have also postulated the possibility to inactivate or even reduce those cells' viability by this drying technology. More specifically, the freezing step followed by sublimation is thought to influence yeast and mould inactivation whereas if freezing slowly, large ice crystals might be formed damaging cell membranes.<sup>39</sup> Given this scenario, with the aim of both decreasing risks of microbial contamination as well as increasing OLE purity in the final product, *Olea europaea* L. extract was freeze-dried for 36 hours. As a result, OLE content was increased from 5.18 to 115.01 mg g<sup>-1</sup> and the amount of yeast and molds was reduced from 18000 to <100 UFC per g after the lyophilization process (Table 7). Therefore, the proposed procedure in this work offers a greener alternative for OLE extraction and purification through the avoidance of organic solvent use in both steps which could be applied to other natural compounds and might be easily implemented in industrial-scale processes meeting current Good Manufacturing Process (cGMP) regulations. Finally, with the aim to protect and improve the efficacy of OLE after oral administration, EVOO based NLCs were proposed in this work. The use of organic solvents was avoided during the nanoformulation process and

a biodegradable matrix composed of glyceryl distearate (Precirol® ATO 5) and organic EVOO was employed. Given this, the HPLC method of the present work was also aimed to indirectly quantify the encapsulation efficiency of the nanoencapsulation process. Formulation components from the NLC supernatants (residual lipids and surfactants) did not interfere in OLE determination, as shown in the specificity assay. Therefore, the developed RP-HPLC-DAD method could be applied for OLE quantification in nanoparticles. OLE content in the NLC-OLE supernatant was found to be  $30.62 \pm 0.06$  mg ml<sup>-1</sup> and thus, the encapsulation efficiency was  $94.09 \pm 0.01\%$ . In light of these results, it could be assumed that the analyte was successfully encapsulated in the EVOO-based NLCs, through the hot-melt emulsification method and therefore, it was validated as an adequate system for OLE encapsulation. We have only found one research article where a HPLC-DAD method was used for OLE determination in nanoemulsions, but the retention time was high (30 min) and no data about linearity nor system suitability were reported.<sup>40</sup> Therefore, to the best of our knowledge this is the first RP-HPLC-DAD method that has been validated for the quantification of OLE in NLCs, which is also applicable to *Olea europaea* L. extracts and olive oil.

#### 3.4. Greenness assessment of the validated RP-HPLC-DAD method

Apart from validating a HPLC method for OLE quantification in the reported samples, offering the conventional standard parameters of good accuracy, precision and selectivity, greenness of the method was also taken into account. With this aim and from an eco-friendly perspective the well-known and established principles of the green chemistry were taken into account to optimize the developed HPLC method.<sup>41</sup> Green chemistry can be summarized by three words: Reduce, Replace and Recycle but when applying it to HPLC techniques only reduce and replace are viable options and thus, in this work, the amount of organic solvent employed for OLE quantification was reduced by shortening the analysis time and increasing the water proportion in the mobile phase composition and sample preparation process. The EAT<sup>29</sup> was used for greenness assessment of the validated HPLC method with regard to its potential health, safety and environmental impact. For this purpose, the EAT was applied to our method and those found in the literature for OLE quantification. The obtained results were used for comparison of our method with those from the literature (Table 8). As shown in Table 8, the total EAT value was strongly influenced by the use of organic solvents for sample pre-treatment and for instance, method D exhibited an EAT value of 69 for samples prepared in water and a value of 97 for those prepared with MeOH. The same occurred for our method (G) in which samples prepared in water (olive leaf extracts and nanoparticles) showed an EAT value of 12.87 whereas for samples of EVOO in which an hydroalcoholic extraction step was conducted, the EAT value was increased to 34.02. Nevertheless, it is worth mentioning that our method displayed the lowest EAT values for samples

**Table 8** Summary of HPLC methods from the literature used for HPLC-EAT ranking

Method	No. of analytes	Type of sample	OLE $R_T$ (min)	Analysis time (min)	Mobile phase	Elution method			Validation	Sample preparation for HPLC	Total EAT
						Isocratic (v/v)	Gradient (steps)	Flow rate (ml min <sup>-1</sup> )			
A <sup>26</sup>	2	EVOO and Olive fruit	10.6	~25	H <sub>2</sub> O-ACN	70 : 30	—	0.5	No	<i>n</i> -Hexane, EtOH	67.20
B <sup>23</sup>	12	Olive leaf	18.0	62	H <sub>2</sub> O-ACN/MeOH (50 : 50)	—	5	1.0	No	MetOH 80%	77.35
C <sup>24</sup>	7	Olive leaf	24.9	70	H <sub>2</sub> O-ACN	—	5	1.0	No	MetOH 50%	135.56
D <sup>22</sup>	1	Olive leaf	27.0	60	H <sub>2</sub> O-ACN	—	8	1.0	No	H <sub>2</sub> O Or MetOH	69.62 97.79
E <sup>4</sup>	3	Stems and roots	50.0	100	H <sub>2</sub> O-MeOH	—	12	1.0	No	MetOH	157.90
F <sup>42</sup>	2	Dietary supplement	11.0	15	H <sub>2</sub> O-ACN	—	6	0.8	Yes	MetOH 50%	114.2
G <sup>a</sup>	1	EVOO, Olive leaf, and NLC	11.0	15	H <sub>2</sub> O-ACN	80 : 20	—	1.2	Yes	H <sub>2</sub> O Or MeOH 50%	12.87 34.02

<sup>a</sup> G is our validated method.

pre-treated with or without organic solvents. From the studied analysis, F was found to be the most similar to our method. The total EAT value for F was found to be 114 because they employed 100 ml of MeOH-H<sub>2</sub>O (50 : 50, v/v) for chromatographic sample preparation. However, EAT could be reduced to ~19 by only decreasing the amount of solvent to 10 ml. Focusing on our method the overall EAT values were decreased to 12.87 for *Olea europaea* L. extracts and nanoparticle analysis whereas the total EAT value for EVOO samples was found to be 34.02. As aforementioned EVOO samples' EAT impact was higher due to the use of MeOH during the sample pre-treatment process.

Nevertheless, it has to be taken into account that other published methods usually employ another extraction step with *n*-hexane and even double-extraction step with ethanol which led to a higher EAT value. Therefore, our method was demonstrated to have the lowest impact on health, safety and environment for OLE quantification.

Beyond olive polyphenols, several other natural compounds have recently gained special attention due to their pleiotropic pharmacological activities and low toxicity. There is a clear trend towards the study of isolated natural polyphenols such as curcumin, resveratrol or quercetin among others. A number of preclinical data state their potential therapeutic effects as well as their unfortunately, typical limiting factors (*i.e.* low bio-availability, poor stability). As a result, many researchers are developing novel formulations to improve the stability and bio-availability of these promising compounds in which analytical techniques are mandatory. RP-HPLC is one of the main preferred techniques for that purpose and researchers take advantage of the amount of published methods for the determination of this kind of molecule. However, most of these methods were developed for the simultaneous determination of a number of molecules in a complex extract with long analysis time and thus, special attention should be paid to precisely adapt the analytical method to the determination of the isolated molecule of interest, with the aim to optimize time and avoid unnecessary waste of organic solvents. We have validated a RP-HPLC-DAD method for the determination of OLE

in the NLC supernatant, aqueous extracts and EVOO samples with a low environmental impact which could be also applied for the determination of other phenolic compounds in a variety of formulations.

## 4. Conclusions

The RP-HPLC-DAD method developed and validated in this work represents an alternative approach for the quantification of OLE in several matrices such as olive oil, *Olea europaea* leaf extracts and lipid nanoparticles with a minimized environmental impact. The validation procedure was carried out according to ICH Q2(R1) guidelines and from an environmental perspective evaluating specificity, linearity, accuracy, precision and greenness. The method proved to be reliable and simple, complying with the requirements of these parameters in the range of 50–420 µg mL<sup>-1</sup>. The LOD was found to be 0.08 µg mL<sup>-1</sup> and LOQ 0.25 µg mL<sup>-1</sup>. RSD obtained in the assays indicates that this method is adequate to quantify OLE in polyphenol rich-olive oil and aqueous and lyophilized extracts of olive leaves as well as nanoparticulated systems obtained through solvent-free methods. Besides, the method was proved to reduce the toxic impact against in regard to the environment, health and safety compared to other HPLC methods. The proposed method could be applied to the determination of other phenolic compounds in a variety of samples.

## Abbreviations

ACN	Acetonitrile
DAD	Diode array detector
DDS	Drug delivery systems
EAT	Environmental Assessment Tool
EVOO	Extra virgin olive oil
EVOO-ph	Extra virgin olive oil rich in polyphenols
HDPE	High Density Polyethylene

1	H <sub>2</sub> O	Water
	HPLC	High performance liquid chromatography
	k'	Capacity factor
	LOD	Limit of detection
5	LOQ	Limit of quantification
	MeOH	Methanol
	N	Number of theoretical plates
	NLC	Nanostructured lipid carrier
10	NLC-OLE	Oleuropein loaded nanostructured lipid carrier
	OLE	Oleuropein
	PVDF	Polyvinylidene fluoride
	R <sub>s</sub>	Resolution
15	R <sub>T</sub>	Retention time
	RP-HPLC-DAD	Reverse phase high performance liquid chromatography coupled with a diode array detector
	RSD	Relative standard deviation
20	T	Tailing factor

## Conflicts of interest

25 The authors declare no competing conflicts of interest.

## Acknowledgements

30 A. Huguet-Casquero thanks the Spanish Ministry of Economy and Competitiveness for the Industrial Doctorate fellowship grant (DI-15-07513). This work was done under the R&D projects of BIOSASUN. The authors wish to thank the ICTS "NANBIOSIS" and the Drug Formulation Unit (U10) of the CIBER-BBN. Furthermore, they acknowledge the support from the University of the Basque Country (UPV/EHU), and the Basque Country Government (Grupos Consolidados, No ref: IT907-16to JL. P). Finally, the authors acknowledge the Laboratorios Innoagral (Grupo Hesperides) for the microbiological assays.

## References

- 45 1 H.E. Billingsley and S. Carbone, *Nutr. Diabetes*, 2018, **8**, 13, DOI: 10.1038/s41387-018-0025-1.
- 50 2 G. Sindona, in *Olives and Olive Oil in Health and Disease Prevention*, ed. V. R. Preedy and R. R. Watson, Academic Press, San Diego, 2010, pp. 95–100.
- 3 M. I. Alarcón Flores, R. Romero-González, A. Garrido Frenich and J. L. Martínez Vidal, *Food Chem.*, 2012, **134**, 2465–2472, DOI: 10.1016/j.foodchem.2012.04.058.
- 55 **Q5** 4 F. Ortega-García and J. Peragón, *J. Sci. Food Agric.*, 2010, **90**, 2295–2300, DOI: 10.1002/jsfa.4085.
- 5 5 European Commission Regulation, *EC No. 432/2012 establishing a list of permitted health claims made on foods, other than those referring to the reduction of disease risk and to children's development and health*, 2012.
- 6 6 EMA monograph, *Assessment report on Olea europaea L., folium*, 2017.
- 7 7 M. L. Castejon, M. Sánchez-Hidalgo, M. Aparicio-Soto, A. González-Benjumea, J. G. Fernández-Bolaños and C. Alarcón-de-la-Lastra, *J. Funct. Foods*, 2019, **58**, 95–104, DOI: 10.1016/j.jff.2019.04.033.
- 10 8 H. Zbidi, S. Salido, J. Altarejos, M. Perez-Bonilla, A. Bartegi, J. A. Rosado and G. M. Salido, *Blood Cells, Mol., Dis.*, 2009, **42**, 279–285, DOI: 10.1016/j.bcmd.2009.01.001.
- 9 9 G. Bisignano, A. Tomaino, R. L. Cascio, G. Crisafi, N. Uccella and A. Saija, *J. Pharm. Pharmacol.*, 1999, **51**, 971–974.
- 15 10 H. F. Al-Azzawie and M.-S. Alhamdani, *Life Sci.*, 2006, **78**, 1371–1377, DOI: 10.1016/j.lfs.2005.07.029.
- 11 11 H. Shamshoum, F. Vlavcheski and E. Tsiani, *Biofactors*, 2017, **43**, 517–528, DOI: 10.1002/biof.1366.
- 12 12 P. Przychodzen, R. Wyszowska, M. Gorzynik-Debicka, T. Kostrzewa, A. Kuban-Jankowska and M. Gorska-Ponikowska, *Anticancer Res.*, 2019, **39**, 1243–1251, DOI: 10.21873/anticancer.13234.
- 13 13 Z. He, X. Deng, P. P. But, V. E. Ooi, H. Xu, S. H. Lee and S. Lee, *Chem. Pharm. Bull.*, 2001, **49**, 1471–1473.
- 14 14 H. Ahmadvand, A. Noori, M. G. Dehnoo, S. Bagheri and R. A. Cheraghi, *Asian Pac. J. Trop. Dis.*, 2014, **4**, S421–S425, DOI: 10.1016/S2222-1808(14)60481-3.
- 15 15 C. Angeloni, M. Malaguti, M. C. Barbalace and S. Hrelia, *Int. J. Mol. Sci.*, 2017, **18**(11), 2230, DOI: 10.3390/ijms18112230.
- 16 16 A. Harvey, R. Edrada-Ebe and R. Quinn, *Nat. Rev. Drug Discovery*, 2015, **14**, 111–129, DOI: 10.1038/nrd4510.
- 17 17 S. C. Edgecombe, G. L. Stretch and P. J. Hayball, *J. Nutr.*, 2000, **130**, 2996–3002.
- 18 18 P. Lin, W. Qian, X. Wang, L. Cao, S. Li and T. Qian, *Biomed. Chromatogr.*, 2013, **27**, 1162–1167, DOI: 10.1002/bmc.2922.
- 19 19 E. González, A. M. Gómez-Caravaca, B. Giménez, R. Cebrián, M. Maqueda, A. Martínez-Férez, A. Segura-Carretero and P. Robert, *Food Chem.*, 2019, **279**, 40–48, DOI: 10.1016/j.foodchem.2018.11.127.
- 20 20 G. Calixto, J. Bernegossi, B. Fonseca-Santos and M. Chorilli, *Int. J. Nanomed.*, 2014, **9**, 3719–3735, DOI: 10.2147/IJN.S61670.
- 21 21 M. Moreno-Sastre, M. Pastor, C. J. Salomon, A. Esquisabel and J. L. Pedraz, *J. Antimicrob. Chemother.*, 2015, **70**, 11-2945–2955, DOI: 10.1093/jac/dkv192.
- 22 22 S. AlShaal, F. Karabet and M. Daghestani, *Determination of the Antioxidant Properties of the Syrian Olive Leaves Extracts and Isolation Oleuropein by HPLC Techniques*, 2019, vol. 6, pp. 97–110.
- 23 23 O. Ghomari, F. Sounni, Y. Massaoudi, J. Ghanam, L. B. Drissi Kaitouni, M. Merzouki and M. Benlemlih, *Biotechnol. Rep.*, 2019, **23**, DOI: 10.1016/j.btre.2019.e00347. **Q6**
- 24 24 S. Ghasemi, D. E. Koohi, M. S. B. Emmamzadehashemi, S. S. Khamas, M. Moazen, A. K. Hashemi, G. Amin, F. Golfakhrabadi, Z. Yousefi and F. Yousefbeyk, *J. Food Sci. Technol.*, 2018, **55**, 4600–4607, DOI: 10.1007/s13197-018-3398-1.

- 1 25 M. Ricciutelli, S. Marconi, M. C. Boarelli, G. Caprioli, G. Sagratini, R. Ballini and D. Fiorini, *J. Chromatogr. A*, 2017, **1481**, 53–63, DOI: 10.1016/j.chroma.2016.12.020.
- 5 26 G. Tamasi, M. C. Baratto, C. Bonechi, A. Byelyakova, A. Pardini, A. Donati, G. Leone, M. Consumi, S. Lamponi, A. Magnani and C. Rossi, *Food Sci. Nutr.*, 2019, **7**, 2907–2920, DOI: 10.1002/fsn3.1142.
- 10 27 International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use ICH, Q2 (R1), Validation of Analytical Procedures: Text and Methodology.
- 15 28 M. Pastor, M. Moreno-Sastre, A. Esquisabel, E. Sans, M. Viñas, D. Bachiller, V. J. Asensio, Á. Del Pozo, E. Gainza and J. L. Pedraz, *Int. J. Pharm.*, 2014, **477**, 485–494.
- 20 29 Y. Yasser Gaber, U. Törnvall, M. A. Kumar, M. Amine and R. Hatti-Kaula, *Green Chem.*, 2011, **13**, 2021–2025, DOI: 10.1039/c0gc00667j.
- 25 30 G. Shabir, *J. Chromatogr. A*, 2003, **987**, 57–66.
- 30 31 D. Ryan, P. D. Prenzler, S. Lavee and K. Robards, *J. Agric. Food Chem.*, 2003, **51**(9), 2532–2538, DOI: 10.1021/jf0261351.
- 35 32 B. Jimenez, A. Sánchez-Ortiz, M. L. Lorenzo and A. Rivas, *Eur. J. Lipid Sci. Technol.*, 2014, **116**, 1634–1646, DOI: 10.1002/ejlt.201400010.
- 40 33 C. Romero, M. Brenes, K. Yousfi, P. García, A. García and A. Garrido, *J. Agric. Food Chem.*, 2004, **52**, 479–484, DOI: 10.1021/jf0305251.
- 45 34 M. Bellumori, L. Cecchi, M. Innocenti, M. Clodoveo, F. Corbo and N. Mulinacci, *Molecules*, 2019, **24**, 2179, DOI: 10.3390/molecules24112179.
- 50 35 E. Susalit, N. Agus, I. Effendi, R. R. Tjandrawinata, D. Nofiarny, T. Perrinjaquet-Moccetti and M. Verbruggen, *Phytomedicine*, 2011, **18**, 251–258, DOI: 10.1016/j.phymed.2010.08.016.
- 55 36 M. de Bock, J. Derraik, C. Brennan, J. Biggs, P. Morgan, S. Hodgkinson, P. Hofman and W. Cutfield, *PLoS One*, 2013, **8**, 3, DOI: 10.1371/journal.pone.0057622.
- 37 O. Castañer, M. Covas, O. Khymenets, K. Nyyssonen, V. Konstantinidou, H. Zunft, R. de la Torre, D. Muñoz-Aguayo, J. Vila and M. Fitó, *Am. J. Clin. Nutr.*, 2012, **95**(5), 1238–44, DOI: 10.3945/ajcn.111.029207.
- 38 L. Oberoi, T. Akiyama, K. Lee and S. J. Liu, *Phytomedicine*, 2011, **18**, 259–265, DOI: 10.1016/j.phymed.2010.07.006.
- 39 S. Bourdoux, D. Li, A. Rajkovic, F. Devlieghere and M. Uyttendaele, *Compr. Rev. Food Sci. Food Saf.*, 2016, **15**, 1056–1066, DOI: 10.1111/1541-4337.12224.
- 40 P. Gharehbeiglou, S. M. Jafari, A. Homayouni, H. Hamishekar and H. Mirzaei, *Food Hydrocolloids*, 2019, **89**, 44–55, DOI: 10.1016/j.foodhyd.2018.10.020.
- 41 P. T. Anastas and J. C. Warner, *Chem. Soc. Rev.*, 2010, **39**, 301–312, DOI: 10.1039/B918763B.
- 42 T. Bertolini, L. Vicentini, S. Boschetti, P. Andreatta and R. Gatti, *J. Pharm. Biomed. Anal.*, 2016, **129**, 198–202, DOI: 10.1016/j.jpba.2016.07.001.